Clinical Trial: REcaticimab for Vascular Efficacy in ReverSing coronary athErosclerotic Plaques: A Multicenter, Prospective, Open-Label, Pragmatic Randomized Controlled Trial(REVERSE) (China)

Posted On: 2026-09-08

China, Sept. 8 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'REcaticimab for Vascular Efficacy in ReverSing coronary athErosclerotic Plaques: A Multicenter, Prospective, Open-Label, Pragmatic Randomized Controlled Trial(REVERSE)'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131830

Registration Time: 2026/09/07

Type: Interventional study

Primary Sponsor: The Second Affiliated Hospital, School of Medicine, Zhejiang University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=288953

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: REcaticimab for Vascular Efficacy in ReverSing coronary athErosclerotic Plaques: A Multicenter, Prospective, Open-Label, Pragmatic Randomized Controlled Trial(REVERSE) (China)